Weekly Rundown: Hantavirus outbreak puts spotlight on antiviral drug discovery gaps

Weekly Rundown: Hantavirus outbreak puts spotlight on antiviral drug discovery gaps Hidden proteins reveal new drug targets, FDA tool upgrades, pharma deals, and more led the news this week. Written byDDN editorial team https://www.drugdiscoverynews.com/weekly-rundown-hantavirus-outbreak-puts-spotlight-on-antiviral-drug-discovery-gaps-17162 May 8, 2026 A cluster of hantavirus infections aboard the cruise ship MV Hondius drew global attention this week. The outbreak has been linked to the Andes strain — the only known hantavirus capable of human-to-human transmission — with five confirmed cases and three deaths reported as of May 6. No licensed antiviral treatment or vaccine currently exists; supportive care focused on managing respiratory, cardiac, and kidney complications remains the standard clinical response. For drug discovery researchers, the outbreak highlights a gap in the antiviral pipeline for emerging and neglected pathogens. Candidate compounds and monoclonal antibodies have shown early promise in preclinical settings, and RNA interference approaches are drawing growing interest — but none have cleared the bar for regulatory approval. – Andrea Corona